home / stock / ocgn / ocgn news

OCGN News and Press, Ocugen, Inc.

Stock Information
Company Name: Ocugen, Inc.
Stock Symbol: OCGN
Market: NYSE
Menu
OCGN OCGN Quote OCGN Short OCGN News OCGN Articles OCGN Message Board
Get OCGN Alerts

News, Short Squeeze, Breakout and More Instantly...
OCGN - UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifi...
OCGN - Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifi...

OCGN - SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 21, 2024) - Faruqi & Faruqi, LLP, a leading national se...

OCGN - Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value

2024-04-19 17:05:07 ET Summary Ocugen, Inc. expects preliminary safety/efficacy data from phase 1/2 study, using OCU-410 for the treatment of patients with GA, in 2024. Preliminary safety/efficacy data from phase 1/2 study, using OCU-401ST for the treatment of patients with Starga...
OCGN - Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy

MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete...

OCGN - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 19, 2024) - Faruqi & Faruqi, LLP, a leading national se...

OCGN - Ocugen stock jumps after $175M securities filing

2024-04-18 06:21:01 ET Read the full article on Seeking Alpha For further details see: Ocugen stock jumps after $175M securities filing
OCGN - DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 14, 2024) - Faruqi & Faruqi, LLP, a leading national se...

OCGN - The 'Undercovered' Dozen From March 2024

2024-04-12 14:30:00 ET Summary Introducing a new recurring series to help you sift through ideas and data on the site: The "Undercovered" Dozen. In this monthly series, we'll cover twelve ideas from the previous month on stocks that receive limited coverage across Seeking Alpha. ...

OCGN - Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN). Investors who purchased Ocugen securities are encouraged to obtain additional information and a...
Next 10